Actively Recruiting
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
Led by Botkin Hospital · Updated on 2025-07-09
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.
CONDITIONS
Official Title
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (> 18 years) with primary IgA nephropathy diagnosed by kidney biopsy
- Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months before joining
- Blood pressure less than 140/90 mm Hg
- 24-hour urinary albumin excretion greater than 300 mg
You will not qualify if you...
- History of kidney transplantation
- Chronic liver disease including hepatitis or active malignancy
- Heart failure with ejection fraction below 40%
- Acute myocardial infarction or stroke within 3 months prior to the trial
- Presence of ANCA in serum
- Ongoing immunosuppressive treatment
- Estimated glomerular filtration rate (eGFR) below 20 ml/min
- Pregnancy or breastfeeding
- Uncontrolled blood pressure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Botkin Hospital
Moscow, Russia
Actively Recruiting
Research Team
E
Evgeny Shytov, PhD
CONTACT
A
Anastasiia Zykova, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here